AI assistant
Merck & Co., Inc. — Director's Dealing 2018
Nov 2, 2018
284_dirs_2018-11-02_b115ce51-02fd-493b-a829-19183aced013.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Merck & Co., Inc. (MRK)
CIK: 0000310158
Period of Report: 2018-11-01
Reporting Person: Schechter Adam H (EVP & Pres-Global Human Health)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-11-01 | Common Stock | M | 277879.0000 | $39.2900 | Acquired | 277879.0000 | Direct |
| 2018-11-01 | Common Stock | S | 132744.0000 | $73.9752 | Disposed | 145135.0000 | Direct |
| 2018-11-01 | Common Stock | S | 145135.0000 | $73.6637 | Disposed | 0.0000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-11-01 | Stock Option (right to buy) | $39.2900 | M | 277879.0000 | Disposed | 2022-05-01 | Common Stock (277879.0000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 55405.9747 | Indirect |
Footnotes
F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.6800 to $73.3900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.4000 to $74.0200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F4: Holdings include shares acquired in dividend reinvestment transactions.
F5: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015.